Orphan Drugs for CNS Diseases: R&D and Market 2014-2024

January 2014 •
130 pages •
Report ID: 2041937 •
Format: PDF

Summary
Table of contents

Report Details

Uncommon nerve disorders - new study explains technological and commercial prospects

What's the future of medicines for rare central nervous system (CNS) disorders? Visiongain's new report gives you predictions for those therapies. Stay ahead. There you explore sales results, technologies, R&D trends, opportunities, and revenue forecasts.

So see what's possible for treating unusual neurological conditions. Avoid missing out. You gain data and financial analysis for that industry and market, appraising its outlooks. Find technological progress and commercial prospects, seeing potential gains.

Read on to explore those treatments and find what their future could be worth.

Forecasts and other analyses for therapy of rare (orphan) neurodegenerative disorders

Our new study reveals sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides forecasting revenues to 2024, that work shows historical results, growth rates, and market shares. There you get feel for technologies, regulatory outlooks, and developments (R&D). You also gain 41 tables, 40 charts, and two interviews with the industry.

Knowledge to help your work and save time, helping your influence

Our report strives to help your business research, analyses, and decisions on treatments for debilitating CNS diseases. There also see how you can save time. And find how you could benefit your authority through better understanding the present and future.

So the following sections explain what you get in that new investigation.

Forecasting of that world market and its main segments - you explore possibilities

What're the secrets of that industry's progress? What's its potential? Discover in our work overall world revenue to 2024 for orphan-drug CNS therapy.

Also in that report you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:
- Huntington's disease (HD)
- Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease, motor neurone disease)
- Myasthenia gravis (MG)
- Other treatment applications.

How will those categories expand? Which classes of therapy can generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales for treating the rarer abnormalities causing neurodegeneration, autoimmune neuromuscular disorder, and other nerve disease.

You also assess top products' futures.

Predictions of leading agents' revenues

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for four marketed drugs:
- Xenazine (tetrabenazine)
- Rilutek (riluzole)
- Mestinon (pyridostigmine)
- Imuran (azathioprine).

There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and potentials.

Our study also divides its overall prediction into geographical regions.

Healthcare in leading national markets - what outlooks for those CNS drug sales?

In developed and developing countries, opportunities for providers of orphan neurological medicines will increase from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
- United States (US)
- Japan
- EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
- BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for those specialist medicines.

Explore, too, how that neur

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager